Application of precision medicine in medical conditions
Keywords:Precision medicine, Umbrella trial, Targeted therapies
The idea of precision medicine came into existence that all patients who received the same therapy do not respond in the same manner and there exists an inter-individual variation. Researchers then found that precision medicine plays a vital role which may lead to treatment failure or toxicity. Precision medicine will provide the right medicine at the right time to the right patients with specific characteristics for a better clinical outcome. It utilizes the information related to a person’s genes, proteins and environment to cure disease. This breaks the model of “one fits for all” and it helps us to sequence DNA which is unique for everyone and to decide therapy based on the genetic information. The difference between the terms “precision medicine” and “personalized medicine” is to be understood since the former will classify people into subpopulations that have difference in their susceptibility to disease and the latter refers to a single drug for a single individual. It has its applications to detect any genetic alterations starting before birth and till old age. Due to this reason, precision medicine has taken over the personalized medicine and the word “precision” means accurate and precise.
Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Aff (Millwood). 2018;37(5):694-701.
Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S et al. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. Oncologist. 2018;23:1520-24.
Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70:125-37.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279-90.
Behera J, Jayaprakash V, Sinha BN. Histone deacetylase inhibitors: a review on class-I specific inhibition. Mini Rev Med Chem. 2015;15:731-50
Peck R. Precision medicine is not just genomics: The right dose for every patient. Ann Rev Pharmacol Toxicol. 2018;58:105 22.
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726 36.
Munnink TO, Henstra MJ, Segerink LI, Movig KL, Brummelhuis-Visser P. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology. Clin Pharmacol Ther. 2016;99:419 31.
Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977-84.
Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin Pharmacol Ther. 2010;87:543 52.
Slamon DJ, Leyland Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783 92.
National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines in Oncology. Non Small Cell Lung Cancer Version 7. 2015.
Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39-44.
Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M et al. Biomarkers for PD 1/PD L1 blockade therapy in non–small cell lung cancer: Is PD L1 expression a good marker for patient selection? Clin Lung Cancer. 2016;17:350 61.
Abdel Rahman O. Correlation between PD L1 expression and outcome of NSCLC patients treated with anti PD 1/PD L1 agents: A meta analysis. Crit Rev Oncol Hematol. 2016;101:75 85.
Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123:107 13.
Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS et al. Activating mutations in the gene encoding the ATP sensitive potassium channel subunit Kir6. 2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838 49.
Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. N Engl J Med. 2006;355:467 77.
Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355:456 66.
Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31:204 9.
Stolar MW. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85:S50 9.
Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563 75.
Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123 33.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA. 2001;286:2270 9.
BlueCross BlueShield Association. Special report: Genotyping for cytochrome P450 polymorphisms to determine drugmetabolizer status. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment. 2004;19.
Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B* 1502 allele and antiepileptic drug induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-8.
SEARCH Collaborative Group. SLCO1B1 variants and statin induced myopathy-a genomewide study. N Engl J Med. 2008;359:789 99
Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther. 2007;81:529 38.
Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M et al. Biomarkers for PD 1/PD L1 blockade therapy in non-small cell lung cancer: Is PD L1 expression a good marker for patient selection? Clin Lung Cancer. 2016;17:350 61.
Azizi F. Precision medicine for endocrinology. Int J Endocrinol Metab. 2016;14:e40283.